Concise review: Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease

Stem Cells Translational Medicine

Volumn 5, Issue 2, 2016, Pages 186-191

  Golpanian, Samuel ^a,b   Schulman, Ivonne H ^a   Ebert, Ray F ^c   Heldman, Alan W ^a   Difede, Darcy L ^a   Yang, Phillip C ^d   Wu, Joseph C ^d   Bolli, Roberto ^e   Perin, Emerson C ^f   Moyé, Lem ^g   Simari, Robert D ^h   Wolf, Ariel ^a   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Department of Surgery ^*  (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Louisville School of Medicine   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Cell dosage; Route of administration; Stem cell

Indexed keywords

ACUTE HEART INFARCTION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW DERIVED MONONUCLEAR CELL; CARDIOVASCULAR DISEASE; CD34 SELECTION; CORONARY ARTERY OCCLUSION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; INJECTION; ISCHEMIC CARDIOMYOPATHY; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEM CELL TRANSPLANTATION; TRANSENDOCARDIAL STEM CELL INJECTION; ALLOTRANSPLANTATION; ANIMAL; AUTOTRANSPLANTATION; CELL COUNT; CYTOLOGY; DOG; EVALUATION STUDY; HEART CATHETER; HEART DISEASES; INTRALESIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; STEM CELL;

ANIMALS; CARDIAC CATHETERS; CELL COUNT; DOGS; EVALUATION STUDIES AS TOPIC; HEART DISEASES; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84969443678     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0101     Document Type: Article

References (42)

1. Halkos ME, Zhao ZQ, Kerendi F et al. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Res Cardiol 2008;103:525-536.
2. Hamamoto H, Gorman JH 3rd, Ryan LP et al. Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: The effect of cell dosage. Ann Thorac Surg 2009;87:794-801.
3. Schuleri KH, Feigenbaum GS, Centola M et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J 2009;30:2722-2732.
4. Hashemi SM, Ghods S, Kolodgie FD et al. A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. Eur Heart J 2008;29:251-259.
5. Quyyumi AA, Waller EK, Murrow J et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J 2011; 161:98-105.
6. Losordo DW, Henry TD, Davidson C et al. Intramyocardial, autologous CD34+cell therapy for refractory angina. Circ Res 2011;109: 428-436.
7. Hare JM, Fishman JE, Gerstenblith G etal. Comparison ofallogeneicvs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA 2012;308:2369-2379.
8. Lee ST, White AJ, Matsushita S et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol 2011;57:455-465.
9. Bolli R, Tang XL, Sanganalmath SK et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 2013;128:122-131.
10. Li CJ, Gao RL, Yang YJ et al. [Effect of intracoronary transplantation of autologous bone marrow mononuclear cells on myocardial ischemia reperfusion injury in mini-swine model]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2008; 30:86-90.
11. Silva GV, Fernandes MR, Cardoso CO et al. A dosing study of bone marrow mononuclear cells for transendocardial injection in a pig model of chronic ischemic heart disease. Tex Heart Inst J 2011;38:219-224.
12. Bolli R, Chugh AR, D’Amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet 2011;378: 1847-1857.
13. Makkar RR, Smith RR, Cheng K et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 2012;379: 895-904.
14. Perin EC, Willerson JT, Pepine CJ et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN trial. JAMA 2012;307: 1717-1726.
15. Perin EC, Silva GV, Zheng Y et al. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J 2012; 163:415-421.
16. Assmus B, Leistner DM, Schächinger V et al. Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: Migratory capacity of administered cells determines event-free survival. Eur Heart J 2014;35:1275-1283.
17. Williams AR, Trachtenberg B, Velazquez DL et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circ Res 2011;108:792-796.
18. Blatt A, Cotter G, Leitman M et al. Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy. Am Heart J 2005;150:986.
19. Santoso T, Siu CW, Irawan C et al. Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: A randomized placebocontrolled trial (END-HF). J Cardiovasc Transl Res 2014;7:545-552.
20. Perin EC, Sanz-Ruiz R, Sanchez PL et al. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE trial. Am Heart J 2014;168:88-95.e2.
21. Perin EC, Silva GV, Assad JA et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol 2008;44:486-495.
22. Vrtovec B, Poglajen G, Lezaic L et al. Comparison of transendocardial and intracoronary CD34+cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 2013;128(suppl 1):S42-S49.
23. Vrtovec B, Poglajen G, Lezaic L et al. Effects of intracoronary Cd34+stem cell transplantation in non-ischemic dilated cardiomyopathy patients: 5-Year follow up. Circ Res 2013;112:165-173.
24. Rigol M, Solanes N, Farr é J et al. Effects of adipose tissue-derived stem cell therapy after myocardial infarction: Impact of the route of administration. J Card Fail 2010;16:357-366.
25. Sherman W, Martens TP, Viles-Gonzalez JF et al. Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med 2006;3 (suppl 1):S57-S64.
26. Keith MC, Tang XL, Tokita Y et al. Safety of intracoronary infusion of 20 million C-kit positive human cardiac stem cells in pigs. PLoS One 2015;10:e0124227.
27. Shake JG, Gruber PJ, Baumgartner WA et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: Engraftment and functional effects. Ann Thorac Surg 2002; 73:1919-1926.
28. Dixon JA, Gorman RC, Stroud RE et al. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation 2009;120(suppl):S220-S229.
29. Quevedo HC, Hatzistergos KE, Oskouei BN et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA 2009;106: 14022-14027.
30. Hatzistergos KE, Quevedo H, Oskouei BN et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010;107:913-922.
31. Williams AR, Suncion VY, McCall F et al. Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc 2013;2:e000140.
32. Williams AR, Hatzistergos KE, Addicott B et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 2013; 127:213-223.
33. Heldman AW, DiFede DL, Fishman JE et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA 2014;311:62-73.
34. Karantalis V, DiFede DL, Gerstenblith G et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res 2014;114:1302-1310.
35. Suncion VY, Ghersin E, Fishman JE et al. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ Res 2014;114: 1292-1301.
36. Williams A, Hatzistergos K, Carvalho D et al. Synergistic effect of human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and restore cardiac function. Circulation 2011;124: A559.
37. Assmus B, Schächinger V, Teupe C et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106:3009-3017.
38. Strauer BE, Brehm M, Zeus T et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002;106:1913-1918.
39. Perin EC, Dohmann HF, Borojevic R et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003;107: 2294-2302.
40. Schuster MD, Kocher AA, Seki T et al. Myocardial neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. Am J Physiol Heart Circ Physiol 2004;287:H525-H532.
41. Tang XL, Rokosh G, Sanganalmath SK et al. Effects of intracoronary infusion of escalating doses of cardiac stem cells in rats with acute myocardial infarction. Circ Heart Fail 2015;8:757-765.
42. Premer C, Blum A, Bellio MA et al. Allogeneicmesenchymal stemcellsrestoreendothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine 2015;2:467-475.